142 related articles for article (PubMed ID: 26426780)
1. The evidence for long-term benefits of restoration of CFTR function continues to grow.
Boyle MP
Am J Respir Crit Care Med; 2015 Oct; 192(7):774-6. PubMed ID: 26426780
[No Abstract] [Full Text] [Related]
2. Ivacaftor CFTR Potentiator Therapy is Efficient for Pancreatic Manifestations in Cystic Fibrosis.
Kounis I; Lévy P; Rebours V
Am J Gastroenterol; 2018 Jul; 113(7):1058-1059. PubMed ID: 29887601
[No Abstract] [Full Text] [Related]
3. Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement.
Heltshe SL; Rowe SM; Skalland M; Baines A; Jain M;
Am J Respir Crit Care Med; 2018 Jun; 197(11):1483-1486. PubMed ID: 29256624
[No Abstract] [Full Text] [Related]
4. A combination therapy for cystic fibrosis.
Brodsky JL; Frizzell RA
Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
[TBL] [Abstract][Full Text] [Related]
5. Foundation receives $3.3-billion windfall for Kalydeco.
Senior M
Nat Biotechnol; 2015 Jan; 33(1):8-9. PubMed ID: 25574617
[No Abstract] [Full Text] [Related]
6. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry.
Elborn JS; Ramsey B; Wainwright C; Boyle M
Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855
[No Abstract] [Full Text] [Related]
7. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.
Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA
Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242
[No Abstract] [Full Text] [Related]
8. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
Jones AM; Barry PJ
Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
[No Abstract] [Full Text] [Related]
9. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
van Koningsbruggen-Rietschel S; Naehrlich L
Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
[No Abstract] [Full Text] [Related]
10. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
McPhail GL; Clancy JP
Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
[TBL] [Abstract][Full Text] [Related]
11. Therapy for cystic fibrosis--the end of the beginning?
Davis PB
N Engl J Med; 2011 Nov; 365(18):1734-5. PubMed ID: 22047565
[No Abstract] [Full Text] [Related]
12. Targeting the basic defect in cystic fibrosis.
Welsh MJ
N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391
[No Abstract] [Full Text] [Related]
13. The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation.
Caverly LJ; Riquelme SA; Hisert KB
Clin Chest Med; 2022 Dec; 43(4):647-665. PubMed ID: 36344072
[TBL] [Abstract][Full Text] [Related]
14. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
15. Ivacaftor for patients with cystic fibrosis.
Wainwright CE
Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205
[TBL] [Abstract][Full Text] [Related]
16. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.
Hisert KB; Heltshe SL; Pope C; Jorth P; Wu X; Edwards RM; Radey M; Accurso FJ; Wolter DJ; Cooke G; Adam RJ; Carter S; Grogan B; Launspach JL; Donnelly SC; Gallagher CG; Bruce JE; Stoltz DA; Welsh MJ; Hoffman LR; McKone EF; Singh PK
Am J Respir Crit Care Med; 2017 Jun; 195(12):1617-1628. PubMed ID: 28222269
[TBL] [Abstract][Full Text] [Related]
17. Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.
Antoniu SA
Expert Opin Investig Drugs; 2011 Mar; 20(3):423-5. PubMed ID: 21303308
[TBL] [Abstract][Full Text] [Related]
18. PharmGKB summary: very important pharmacogene information for CFTR.
McDonagh EM; Clancy JP; Altman RB; Klein TE
Pharmacogenet Genomics; 2015 Mar; 25(3):149-56. PubMed ID: 25514096
[No Abstract] [Full Text] [Related]
19. Mutation-specific therapy in cystic fibrosis: the earlier, the better.
Tümmler B
Lancet Respir Med; 2013 Oct; 1(8):591-592. PubMed ID: 24461654
[No Abstract] [Full Text] [Related]
20. Lung clearance index response in patients with CF with class III CFTR mutations.
Kane M; Gonska T; Jensen R; Avolio J; Klingel M; Stanojevic S; Ratjen F
Thorax; 2016 May; 71(5):476-7. PubMed ID: 26944510
[No Abstract] [Full Text] [Related]
[Next] [New Search]
